Press Release

India Lopinavir & Ritonavir Market to Grow at an Impressive Rate through 2025

Increasing number of COVID-19 cases across the country to drive the growth of India lopinavir & ritonavir market

According to TechSci Research report, India Lopinavir & Ritonavir Market By Dosage Form (Tablet, Capsule, Oral Solution), By Dosage (Lopinavir 200mg/ Ritonavir 50mg Co-formulated Tablet, Lopinavir 100mg/ Ritonavir-25mg Co-formulated Capsule, Lopinavir 400mg/ Ritonavir 100mg/ 10ml Oral Solution), By Application (HIV, COVID-19, Hepatitis C, Others), By Distribution Channel (Hospitals & Clinics, Drug Stores/Pharmacies, Online, Others), By End User (Adults v/s Children (14days of age & above)), By Region, Forecast & Opportunities, 2025, the India lopinavir & ritonavir market is expected to grow at an impressive rate during the forecast period on account of the growing use of the drug combination in treating various diseases such as HIV, COVID-19, Hepatitis C, among others. Additionally, growing use of this combination in treatment of COVID-19, which at present, has no approved drug or treatment, is expected to positively influence the market growth in the country. Furthermore, the ICMR has received approval from the Drug Controller General of India to allow the use of this combination for treatment of novel coronavirus disease. This is expected to create lucrative opportunities for the market growth. However, this is an antiretroviral combination which is approved for the treatment of HIV and has no approval or clinical evidence for treating COVID-19 disease. It is just being used since no harmful effects have been observed. Additionally, associated side effects such as diarrhea, nausea, abdominal pain, vomiting, headache, among others, might hamper the growth of market. Besides, this combination is quite expensive, and availability of other drugs and generics might hinder the market growth over next few years. Furthermore, this combination should be avoided or very cautiously used with heart patients especially those suffering from ischemic heart disease or cardiomyopathies. This in turn might negatively impact the market growth through 2025.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on" India Lopinavir & Ritonavir Market"

https://www.techsciresearch.com/report/india-lopinavir-ritonavir-market/4718.html

The India lopinavir & ritonavir market is segmented based on dosage form, dosage, application, distribution channel, end user company and region. Based on dosage form, the market can be categorized into tablet, capsule and oral solution. The tablets segment is expected to dominate the market since they are inexpensive, safe and effective in delivering oral medication. On the other hand, the capsules segment is expected to hold a significant market share on account of their fast action attribute. They breakdown quickly as compared to the tablets. Additionally, they have higher bioavailability as a result of which, more drug is likely to enter the bloodstream. Also, they are tasteless hence do not leave any unpleasant taste or odor. Based on application, the market can be fragmented into HIV, COVID-19, Hepatitis C and others. The HIV segment is expected to dominate the market since this combination of drugs is primarily used for the treatment of HIV and have the approval for that from the FDA. On the contrary, COVID-19 segment is expected to register significant growth on account of the increasing use of this combination of drugs for treating COVID-19 disease that recently grasped the whole country.

AbbVie India, Hetero Drugs Ltd., Aurobindo Pharmaceuticals Limited, Cipla, Mylan India, Lupin Ltd., Macleods Pharmaceuticals Limited, Discovery Laboratories Pvt. Ltd., SMS Pharmaceuticals, PCD Pharmaceuticals, Aspire Lifesciences Pvt. Ltd., Rewine Pharmaceutical, Wellona Pharmaceutical, Acebright India Pvt. Ltd., Dr. Reddy’s Laboratories and others are some of the leading players operating in India lopinavir & ritonavir market. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4718

Customers can also request for 10% free customization on this report.

India lopinavir & ritonavir market is expected to witness significant growth during the forecast period on account of the increase in the COVID-19 cases increasing in the country, which at present has no available treatment. Additionally, the Indian experts say that they will minimum take 1.5 years to develop a potential vaccine against this disease. Looking at the current scenario, the department of pharmaceuticals held a meeting with the major players operating in the Indian market and asked them to ramp up the production lopinavir & ritonavir and keep the stocks ready for emergency situations. This is further expected to create lucrative opportunities for the market growth over the next few years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.

“India Lopinavir & Ritonavir Market By Dosage Form (Tablet, Capsule, Oral Solution), By Dosage (Lopinavir 200mg/ Ritonavir 50mg Co-formulated Tablet, Lopinavir 100mg/ Ritonavir-25mg Co-formulated Capsule, Lopinavir 400mg/ Ritonavir 100mg/ 10ml Oral Solution), By Application (HIV, COVID-19, Hepatitis C, Others), By Distribution Channel (Hospitals & Clinics, Drug Stores/Pharmacies, Online, Others), By End User (Adults v/s Children (14days of age & above)), By Region, Forecast & Opportunities, 2025”, has evaluated the future growth potential of India lopinavir & ritonavir market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India lopinavir & ritonavir market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]